Note: This research paper has been officially retracted by the publisher. The following summary describes the authors' original claims and methodology, but the findings should be viewed with extreme caution given the retraction status.
Abstract
Retinoblastoma (RB) is a prevalent childhood neoplasm. This study investigated the hypothesis that silencing cyclin‑dependent kinase regulatory subunit 1B (CKS1B) inhibits RB cell progression through the MEK/ERK signaling pathway. CKS1B expression was analyzed in RB tissues and cell lines (SO‑RB50, Y79, HXO‑RB44). Results indicated that CKS1B is significantly overexpressed in RB. Silencing CKS1B via shRNA led to reduced cell proliferation, migration, invasion, and angiogenesis, while increasing apoptosis. These effects were linked to the suppression of the MEK/ERK pathway, suggesting CKS1B as a potential therapeutic target.
Introduction
Retinoblastoma is the most common intraocular malignancy in children. While the primary driver is the loss of the RB1 gene, secondary molecular alterations are necessary for tumor progression. CKS1B, a member of the cyclin kinase subunit family, has been implicated in various cancers by promoting cell cycle progression. This study aimed to elucidate the role of CKS1B in RB and its underlying molecular mechanisms.
Expression Profiling of CKS1B
The researchers first established the expression levels of CKS1B in clinical samples and established cell lines. Using RT-qPCR and Western blot analysis, they compared RB tumor tissues from 35 patients with adjacent healthy retina tissues. Furthermore, they screened three RB cell lines (SO-RB50, Y79, and HXO-RB44) against a normal retinal vascular endothelial cell control (ACBRI-181).
As shown in Figure 1, CKS1B mRNA and protein levels were significantly elevated in tumor tissues compared to adjacent healthy tissues. Similarly, all three RB cell lines exhibited markedly higher CKS1B expression than the normal control, with SO-RB50 and HXO-RB44 showing the highest levels.
Functional Impact of CKS1B Silencing
To determine the functional role of CKS1B, the researchers employed shRNA-mediated knockdown in SO-RB50 and HXO-RB44 cells. Silencing CKS1B resulted in several key phenotypic changes:
- Reduced Proliferation: MTT assays showed a significant decrease in cell viability and growth over 72 hours.
- Cell Cycle Arrest: Flow cytometry revealed an increase in cells in the G0/G1 phase, indicating inhibited progression.
- Inhibited Metastatic Potential: Transwell and Matrigel assays demonstrated significantly reduced migration and invasion capabilities.
- Suppressed Angiogenesis: In a lumen formation assay, CKS1B-silenced cells formed fewer tube-like structures, suggesting a decrease in the tumor's ability to recruit new blood vessels.
The MEK/ERK Signaling Pathway
The study explored the molecular mechanism behind these observations, focusing on the MEK/ERK pathway. Western blot analysis revealed that CKS1B knockdown led to a decrease in the phosphorylation (activation) of MEK and ERK. This suppression was accompanied by downregulated expression of downstream targets including Cyclin D1, PCNA (proliferation markers), and VEGF/bFGF (angiogenic factors), while pro-apoptotic signaling was enhanced.
Conclusion and Retraction Note
The authors concluded that CKS1B promotes RB progression by activating the MEK/ERK pathway and that its downregulation could serve as a therapeutic strategy. However, it is imperative to note that this article has been retracted. Retractions typically stem from concerns regarding data reliability or experimental integrity. Consequently, while the study outlines a plausible molecular mechanism, the findings cannot be considered validated scientific evidence.
Summary updated